Sensei Biotherapeutics, Inc. (SNSE) shares fell 33.29 percent to $11.73, down $5.85 on Friday after reporting results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA. The data were presented at the ESMO Congress 2025.
The stock traded between $10.52 and $17.50 during the session, compared with a previous close of $17.58 on the Nasdaq. Volume reached 744,100 shares, well above the average of 18,937.
The 52-week range is between $5.00 and $18.35.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.